

# Cecilia Beatrice Chighizola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4209435/publications.pdf>

Version: 2024-02-01

81  
papers

2,908  
citations

182225

30  
h-index

198040

52  
g-index

89  
all docs

89  
docs citations

89  
times ranked

2844  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 346-353.	2.9	2
2	Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction. <i>Autoimmunity Reviews</i> , 2022, 21, 102990.	2.5	1
3	Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210803.	1.2	4
4	Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 841785.	1.6	9
5	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). <i>Thrombosis and Haemostasis</i> , 2022, 122, 1612-1620.	1.8	0
6	Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
7	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	1.5	60
8	Anti- $\phi$ phospholipid antibodies and reproductive failures. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13258.	1.2	13
9	Antibodies and diagnostic tests in antiphospholipid syndrome. , 2021, , 565-574.		1
10	Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies: reply. <i>Rheumatology</i> , 2021, 60, e110-e112.	0.9	0
11	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	1.0	19
12	Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. <i>Current Rheumatology Reports</i> , 2021, 23, 10.	2.1	12
13	Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes. <i>European Journal of Anaesthesiology</i> , 2021, 38, 916-922.	0.7	8
14	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicines</i> , 2021, 9, 671.	1.4	17
15	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021, 60, 1114-1124.	0.9	41
16	Editorial: Therapeutic Implications for Pregnant Women With Systemic Autoimmune Diseases and Their Children. <i>Frontiers in Pharmacology</i> , 2021, 12, 773970.	1.6	0
17	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 938-946.	0.4	1
18	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	0.9	53

#	ARTICLE	IF	CITATIONS
19	The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy. <i>Frontiers in Immunology</i> , 2020, 11, 2084.	2.2	30
20	16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1601-1615.	0.8	27
21	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 265.	1.6	33
22	Chronic non-bacterial osteomyelitis: a retrospective international study on clinical manifestations and response to treatment. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1255-1262.	0.4	3
23	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019, 10, 1948.	2.2	33
24	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	0.8	13
25	Lung Disease in Antiphospholipid Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 278-294.	0.8	10
26	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	2.5	106
27	FRIO186...HYDROXYCHLOROQUINE ON THE TOP OF STANDARD TREATMENT WITH LOW DOSE ASPIRIN AND LOW MOLECULAR WEIGHT HEPARIN SIGNIFICANTLY REDUCES THE PROBABILITY OF PREGNANCY MORBIDITY IN WOMEN WITH MULTIPLE POSITIVITY FOR ANTI-PHOSPHOLIPID ANTIBODIES. , 2019, , .		0
28	ABO201...THE PATHOGENIC EFFECTS OF IMMUNE COMPLEXES CONTAINING SCLERODERMA-SPECIFIC AUTOANTIBODIES IN ENDOTHELIAL CELLS. , 2019, , .		0
29	FRIO185...HYDROXYCHLOROQUINE FOR THE PREVENTION OF RELAPSES IN A SERIES OF 812 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE HIBISCUS RETROSPECTIVE STUDY. , 2019, , .		0
30	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	2.5	44
31	â€œDisease knowledge indexâ€ and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	0.8	25
32	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018, 90, 1-27.	3.0	60
33	Beyond thrombosis: Anti-Î²2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 90, 76-83.	3.0	60
34	Management of Thrombotic Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 419-426.	1.5	26
35	Therapy for antiphospholipid miscarriages: Throwing the baby out with the bathwater?. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12792.	1.2	3
36	The use of biologics and small molecules in pregnant patients with rheumatic diseases. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 987-998.	1.3	39

#	ARTICLE	IF	CITATIONS
37	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018, 20, 187.	1.6	33
38	Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. <i>Current Rheumatology Reports</i> , 2018, 20, 44.	2.1	8
39	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018, 9, 1388.	2.2	51
40	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	3.5	95
41	Mechanisms of Action of the Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 31-46.	0.1	1
42	Does APS Impact Women's Fertility?. <i>Current Rheumatology Reports</i> , 2017, 19, 33.	2.1	21
43	The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 401-423.	2.9	56
44	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. <i>Arthritis Research and Therapy</i> , 2017, 19, 156.	1.6	14
45	Serum chemerin in systemic sclerosis: a novel marker of early diffuse disease?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 223-224.	0.4	2
46	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016, 9, 389-400.	1.0	31
47	The hidden world of anti-phospholipid antibodies and female infertility: A literature appraisal. <i>Autoimmunity Reviews</i> , 2016, 15, 493-500.	2.5	31
48	Antibodies and Diagnostic Tests in Antiphospholipid Syndrome. , 2016, , 495-501.		0
49	Antiphospholipid Antibodies and Infertility: A Gene Expression Study in Decidual Stromal Cells. <i>Israel Medical Association Journal</i> , 2016, 18, 146-9.	0.1	8
50	Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2015, 27, 476-482.	2.0	35
51	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches. <i>Journal of Immunology Research</i> , 2015, 2015, 1-20.	0.9	48
52	The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. <i>Lupus</i> , 2015, 24, 980-984.	0.8	52
53	Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings?. <i>Journal of Rheumatology</i> , 2015, 42, 158-160.	1.0	12
54	Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against Î² <sub>2</sub> -Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti-“Domain 1 to Anti-“Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2015, 67, 2196-2204.		94

#	ARTICLE	IF	CITATIONS
55	Antiphospholipid antibodies and infertility. <i>Lupus</i> , 2014, 23, 1232-1238.	0.8	29
56	Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1505-1517.	1.3	25
57	Reply. <i>Arthritis Care and Research</i> , 2014, 66, 966-967.	1.5	1
58	Toll-like receptor 4 and $\beta_2$ glycoprotein I interaction on endothelial cells. <i>Lupus</i> , 2014, 23, 1302-1304.	0.8	23
59	Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2014, 47, 6-16.	2.9	23
60	New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I $\beta_2$ -Glycoprotein-I Antibodies. <i>Current Rheumatology Reports</i> , 2014, 16, 402.	2.1	59
61	14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. <i>Autoimmunity Reviews</i> , 2014, 13, 795-813.	2.5	161
62	Phospholipid Autoantibodies (Nonanticardiolipin)-Antiprothrombin Antibodies. , 2014, , 741-749.		2
63	New oral anticoagulants in thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2014, 23, 1279-1282.	0.8	34
64	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. <i>Arthritis Research and Therapy</i> , 2014, 16, 209.	1.6	99
65	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 609-615.	0.5	132
66	Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. <i>Arthritis Research and Therapy</i> , 2014, 16, R53.	1.6	153
67	$\beta_2$ -glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , 2014, 55, 42-50.	3.0	52
68	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	2.5	224
69	The Geoepidemiology of Autoimmune Liver Disease. , 2014, , 27-43.		0
70	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. <i>Immunologic Research</i> , 2013, 56, 432-438.	1.3	57
71	Estimated Frequency of Antiphospholipid Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature. <i>Arthritis Care and Research</i> , 2013, 65, 1869-1873.	1.5	275
72	A5.5â€¦Antibodies against Domain I of $\beta_2$ Glycoprotein I in Antiphospholipid Antibody Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A31.3-A32.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Pathophysiology of the antiphospholipid syndrome (APS). <i>Revue De Medecine Interne</i> , 2012, 33, A2-A4.	0.6	7
74	N-TproBNP as Biomarker in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 292-301.	2.9	9
75	Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: Pros and Cons. <i>Autoimmunity Reviews</i> , 2012, 11, 568-571.	2.5	22
76	The role of environmental estrogens and autoimmunity. <i>Autoimmunity Reviews</i> , 2012, 11, A493-A501.	2.5	85
77	Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis. <i>Current Vascular Pharmacology</i> , 2012, 10, 639-646.	0.8	12
78	Introduction. <i>Autoimmunity Reviews</i> , 2011, 10, 239-240.	2.5	12
79	Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 219-230.	0.3	4
80	The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. <i>Autoimmunity</i> , 2009, 42, 257-259.	1.2	38
81	Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some) <i>TJ ETQq1</i> 1.0784314rgBT / 1.017	1.0784314	17